The final case is presented by Dr Adam, showcasing a 79-year old patient with multiple diagnoses and rapid progression of geographic atrophy.
Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.
John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.
Patients’ reluctance to visit a clinic during the COVID-19 pandemic is pushing retina specialists to optimize therapy.
Reliable visualization tools, especially those indicated for ocular use, are crucial for success.
Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
CAM encourages corneal healing in patients with ocular surface disease.
Long-term sustained-release therapy pays off in management of chronic, vision-threatening disease.
Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.
Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).
Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.
This article is produced by iCare Finland for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.
Cell and gene therapies in development for unmet needs.
Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.
Examining an intraocular implant that can sharpen vision for patients as disease progresses.
Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025.
Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).
Among the promising areas of retinal disease research are innovative approaches targeting pan-vascular endothelial growth factor inhibition.
Tunde Peto, MD, PhD, discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.
A review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.
The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.
Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
Franklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.
The DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.
Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.